August 25, 2017
SymBio Pharmaceuticals Limited
Fuminori Yoshida
Representative Director
President and Chief Executive Officer(Securities Code: 4582)
Completion of Payment for Subscription for the 42nd Stock Acquisition Rights
by Third-Party Allotment
TOKYO, Japan, August 25, 2017 -- SymBio Pharmaceuticals Limited (Headquarters: Tokyo) announced thatpayment of ¥32,560,000 has been completed today for the subscription for the 42nd stock acquisition rights by thirdparty allotment resolved at its board of directors’ meeting on August 9, 2017.

Summary of the 42nd stock acquisition rights
Date of allotment
August 25, 2017Number of stock acquisition rights issued 88,000 units
Issue price¥370 per stock acquisition right (total of ¥32,560,000)
Number of residual securities: 8,800,000 shares
There is no maximum exercise price.
Number of residual securities from theThe minimum exercise price is ¥108, but even at the minimum
issuance
exercise price, the number of residual securities is 8,800,000
shares.
Amount of funding¥1,909,560,000 (Estimated net proceeds)
Initial exercise price: ¥215
On February 26, 2018, the exercise price shall be amended toan amount equivalent to 90% of the closing price of SymBio’s
common shares on February 23, 2018, but in the event that theExercise price and exercise priceprice is below the minimum exercise price, the minimum
amendment provisions
exercise price shall be the exercise price after amendment.
The warrants are not classified as an MSCB, etc. as defined inRule 410, Paragraph 1 of the Securities Listing Regulations set
forth by the Tokyo Stock Exchange.
Method for subscription or allotment

The rights shall be allotted by third-party allotment.

Entity for the allotment
Exercise period of the warrants

SBI SECURITIES Co., Ltd.
From August 26, 2017 to August 27, 2018

(Note) For further details, please refer to the press release dated August 9, 2017, “Notice of theSubscription for the 42nd Stock Acquisition Rights by Third-Party Allotment”.

Note:

This document does not constitute an investment solicitation for any securities for sale. This document has been prepared to publicly
announce matters related to the issuance of the 42nd stock acquisition rights, and not for the purpose of soliciting investment. This
document does not constitute an offer of investment in nor solicitation for purchase of the 42nd stock acquisition rights within theUnited States. Regarding the 42nd stock acquisition rights, SymBio has not registered, and is not scheduled to register, any of themunder the United States Securities Act of 1933. The securities may not be offered or sold in the United States without a registrationor an exemption from registration under the United States Securities Act of 1933. No offer of securities in the United States will bemade in connection with this transaction.

-1-[Contact]
Investor Relations
Tel: +81(0)3 5472 1125

About SymBio Pharmaceuticals Limited
SymBio Pharmaceuticals Limited was established in March, 2005 by Fuminori Yoshida who previously served
concurrently as Corporate VP of Amgen Inc. and founding President of Amgen Japan. In May, 2016 theCompany incorporated its wholly-owned subsidiary in the U.S., called SymBio Pharma USA, Inc.
(Headquarters: Menlo Park, California, President: Mr. Fuminori Yoshida). The Company’s underlying corporate
mission is to “deliver hope to patients in need” as it aspires to be a leading global specialty biopharmaceuticalcompany dedicated to addressing underserved medical needs with main therapeutic focus in oncology,
hematology and pain management.

Note:This document does not constitute an investment solicitation for any securities for sale. This document has been prepared to publicly
announce matters related to the issuance of the 42nd stock acquisition rights, and not for the purpose of soliciting investment. This
document does not constitute an offer of investment in nor solicitation for purchase of the 42nd stock acquisition rights within theUnited States. Regarding the 42nd stock acquisition rights, SymBio has not registered, and is not scheduled to register, any of themunder the United States Securities Act of 1933. The securities may not be offered or sold in the United States without a registrationor an exemption from registration under the United States Securities Act of 1933. No offer of securities in the United States will bemade in connection with this transaction.

-2-